Reaching 115 Nanometers: A Milestone in VYTA’s Lipid Particle Research
At VYTA, “precision formulated skincare” starts at the laboratory bench—with a formula, a question, and measurements that help us decide what comes next.
Our latest development milestone: a peptide-containing lipid dispersion with a measured average particle size of approximately 115 nanometers.
It is a meaningful step in our work toward a lipid delivery system for future VYTA formulations, including Copper Renew™.
What Does 115 Nanometers Mean?
A nanometer is one-billionth of a meter. At approximately 115 nanometers, these particles are far too small to see individually with the naked eye.
That number describes their measured size in suspension. It does not mean every particle is exactly 115 nanometers, and it does not describe the size of the peptide molecules themselves.
For a skincare developer, particle size is one useful way to track how a formulation responds to changes in ingredients and processing.
What the Laboratory Measured
Our experimental dispersion contained phospholipids and Palmitoyl Tripeptide-5, a cosmetic peptide we are investigating for future formulations.
Testing used dynamic light scattering, or DLS, to estimate particle size from how particles move in a liquid. The samples were diluted 100-fold with deionized water and measured at 25°C.
Two measurement sets from the peptide-containing preparation returned the following results:
| Measurement | Set B | Set B2 |
|---|---|---|
| Effective particle diameter | 114.2 nm | 116.0 nm |
| Polydispersity index | 0.242 | 0.214 |
Together, those effective diameter measurements support describing the result as approximately 115 nanometers.
The polydispersity index, or PDI, provides information about the spread of particle sizes. We track it alongside average diameter because a single size measurement cannot describe the entire dispersion.
These were repeated measurements of one preparation. Confirming the result across separately manufactured batches is the next step.
The Process Matters
Reaching this size took several rounds of formulation and processing work.
Our development process includes forming a lipid film, hydrating it under controlled conditions, and applying sonication. Throughout that process, we track variables such as temperature, hydration time, ingredient ratios, and processing conditions.
One observation stood out during the latest round: the blank preparation showed visibly incomplete hydration during a stepped warming sequence, while the peptide-containing preparation received more time to warm before hydration proceeded.
The blank also produced substantially larger measured particle sizes.
That comparison gives us a useful direction for further investigation. Because thermal history and peptide content both differed, this experiment cannot establish which factor caused the size difference. Our next round will help separate those effects.
What This Result Tells Us—and What Comes Next
The current data show that our experimental process produced a lipid dispersion with an effective particle diameter near our development target.
Particle size alone does not establish how much peptide is encapsulated, confirm the particles’ internal structure, or demonstrate delivery through skin. Those questions require additional testing.
Our next priorities are to repeat the preparation, assess how its size changes during storage, and determine how it behaves when incorporated into a prototype serum.
Building Copper Renew Through Measured Progress
This research is helping guide the development of Copper Renew, our forthcoming multi-peptide formulation.
The approximately 115-nanometer result belongs to an experimental dispersion. Finished-formula performance and stability still need to be evaluated.
For VYTA, this is the work behind precision formulation: make the sample, measure the result, understand its limits, and use the evidence to improve the next batch.
Engineered for Skin Performance. Built through measured progress.